Gelonghui, April 18, 丨 Zhongji Longevity Science (00767.HK) announced that on April 18, 2024, Shenzhen Zhongji Health Science Co., Ltd., a wholly-owned subsidiary of the company, and Sichuan Zhongji Guande Biotechnology Co., Ltd., an indirect non-wholly-owned subsidiary of the company, entered into a joint venture agreement with Sichuan Zhongnongyun Qianghang Data Technology Group Co., Ltd. to establish a joint venture in China. At the time of establishment of the joint venture, CGC Guande will own 51% of the shares, Zhongji Health will own 25%, and Zhongnongyun will own 24% of the shares.
The joint venture will be mainly engaged in the development of minimally invasive technology and the application of interstitial technology for the development of new clinical management of hypertension and diabetes A+ in China, as well as trade in related biological products.
The initial registered capital of the joint venture is RMB 2,000,000, and CGI Guande, Zhongji Health and Zhongnongyun will contribute in proportion to their respective equity interests in the joint venture.
The Group is mainly engaged in the business of providing health consulting and medical products trading through its subsidiary, Zhongji Guande, in the business of providing biomedical products trading. The board of directors believes that the longevity biological products and biotechnology market has good prospects for development. The establishment of a joint venture is in line with the Group's business development strategies and plans and will benefit the Group's future business development. The board of directors believes that the joint venture agreement will further improve the Group's layout in the field of longevity science. Under the main business “Longevity Biological Products and Longevity Management”, it will provide the Group with a good opportunity to expand its business scope to biotechnology technology business, strengthen and improve related industrial chains and product chains, open up new revenue sources for the company, and bring stable and continuous revenue growth to the Group in the long run.